5:57 PM
 | 
Jun 06, 2013
 |  BC Extra  |  Top Story

FDA panel backs looser Avandia REMS

A joint meeting of FDA's Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management advisory committees voted on Thursday to loosen the REMS for diabetes drug Avandia rosiglitazone from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Among the 26 members on the panel, 13 voted to modify the REMS, seven voted to remove the REMS, five voted to maintain the REMS and...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >